Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Synthetic DMARDs May Blunt Pneumococcal Vaccine Response in Systemic Sclerosis

Scott Baltic  |  January 24, 2018

NEW YORK (Reuters Health)—Pneumococcal vaccination yields a satisfactory antibody response in patients with systemic sclerosis (SSc), but synthetic disease-modifying antirheumatic drugs (DMARDs) might reduce the vaccine response in these individuals, according to a report from Sweden. The prospective study, published online Jan. 8 in Rheumatology, evaluated the response to either pneumococcal conjugate vaccine (PCV13) or…

U.S. Appeals Court Invalidates J&J Patent on Remicade

Reuters Staff  |  January 24, 2018

(Reuters)—A U.S. appeals court on Tuesday upheld a ruling that invalidated a crucial Johnson & Johnson patent on its blockbuster rheumatoid arthritis drug, Remicade (infliximab), limiting J&J’s ability to seek damages from Pfizer Inc. over its launch of a lower-cost version of the drug. The U.S. Circuit Court of Appeals for the Federal Circuit affirmed…

U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

Yasmeen Abutaleb  |  January 24, 2018

WASHINGTON (Reuters)—The U.S. Drug Enforcement Administration said on Tuesday it had changed a regulation to allow more healthcare professionals to prescribe a medication used to treat opioid addiction, opening up access in rural America where there are few doctors.1 Prior to 2000, only physicians could treat those with opioid addiction and had to register with…

Sleep Tips for RA Patients & Rheumatologists

Carina Stanton  |  January 23, 2018

A lack of quality sleep may exacerbate depression and pain in patients with rheumatoid arthritis, according to Michael R. Irwin, MD. Here are some tips for rheumatologists on how to discuss sleep with patients and help patients reduce sleep disturbance…

Potential Therapeutic Target for SpA

Lara C. Pullen, PhD  |  January 23, 2018

Innate lymphoid cells (ILCs) in the joints of patients may drive the pathology of spondyloarthritis through the production of granulocyte colony-stimulating factor (GM-CSF). A recent study found that both GM-CSF-producing CD4 T cells and the GM-CSF+ Th17 cells expressed high levels of GPR65—indicating that both GM-CSF and GPR65 may be therapeutic targets for spondyloarthritis…

EU Approves Certolizumab Pegol for Pregnant & Nursing Patients

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2018

In the EU, certolizumab pegol has been approved for use in pregnant and nursing women with chronic rheumatic disease…

Delaware Sues Opioid Manufacturers, Distributors Over Epidemic

Nate Raymond  |  January 22, 2018

(Reuters)—Delaware on Friday became the latest state to file a lawsuit accusing corporations of helping fuel the national opioid epidemic, suing a wide range of companies involved in making, distributing and selling prescription painkillers.1 The lawsuit, filed by Delaware Attorney General Matt Denn in a state court, targeted drugmakers Purdue Pharma LP and Endo International…

Use Epidural Steroid Injections Cautiously in Patients with Fracture Risk

Scott Baltic  |  January 22, 2018

NEW YORK (Reuters Health)—Use of epidural steroid injections (ESIs) “should be approached with prudence,” particularly in patients who are at risk for osteoporotic fractures, such as women of postmenopausal age, according to authors of a systematic review. Although the literature presents a mixed picture, ESIs in doses as low as 80 mg methylprednisolone equivalents seem…

Kentucky Accuses McKesson of Helping Fuel the Opioid Epidemic

Nate Raymond  |  January 22, 2018

(Reuters)—Kentucky’s attorney general on Monday accused drug distributor McKesson Corp. of helping fuel the opioid epidemic by failing to halt shipments of suspiciously large or frequent orders by pharmacies of prescription painkillers. The complaint by Kentucky Attorney General Andy Beshear was filed in a state court and was one of a flurry of lawsuits by…

2018 CPT Coding Updates

From the College  |  January 19, 2018

Each year the American Medical Association’s CPT code manual is revised to delete codes and/or guidelines, and to add or revise codes to reflect current technologies, techniques and services. Medicare and all other payers are switching to the new 2018 CPT codes for X-rays of the chest. The original codes for a chest X-ray were…

  • « Previous Page
  • 1
  • …
  • 363
  • 364
  • 365
  • 366
  • 367
  • …
  • 815
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences